Investigations into the efficacy of newer medications in membranous nephropathy including mycophenolate mofetil and rituximab are ongoing at the Glomerular Center (ASN Abstract 2005: Rituximab in Glomerular Disease); (ASN Abstract 2005: Mycophenolate mofetil vs. Intravenous cyclophosphamide for severe lupus nephritis: subgroup analysis of patients with membranous nephropathy)
Completed Studies and Trials
Anti-C5 monoclonal antibody: A recently completed multicenter double blinded randomized trial in 116 patients of a humanized anti-C5 monoclonal antibody in membranous nephropathy was examined for reduction of proteinuria and safety profile as outcomes. Although some patients experienced reductions in proteinuria, at final evaluation, there was no significant decrease in proteinuria for the entire group (Abstract ASN 2004)
The North American Trial of Cyclosporine: A randomized, double blind, multicenter trial of cyclosporine vs. placebo in 50 patients with steroid resistant membranous nephropathy. The results showed greater partial and complete remissions of proteinuria in the cyclosporine group.
Mycophenolate Mofetil: A pilot study of mycophenolate mofetil (Cellcept) in 16 patients with multiple medication resistant membranous nephropathy showed approximately one-half had a partial or complete remission of proteinuria. (Miller G, Radhakrishnan J, Appel GB. Mycophenolate mofetil in the treatment of resistant membranous nephropathy. Amer J Kid Dis 36: 250-256, 2000.)
(Cattran DC, Appel GB, Hebert LA, Hunsicker L, Pohl M, Hoy WE, Maxwell DR, Kunis CL, for the North American Nephrotic Syndrome Study Group. Cyclosporine in Steroid Resistant Membranous Nephropathy: A randomized trial. Kidney Int.59: 1484-1490, 2001.)